Video

Increased Risk of Tardive Dyskinesia

Author(s):

John J. Miller, MD

How could drugs that block post-synaptic dopamine 2 receptors increase the risk for tardive dyskinesia over time?

John J. Miller, MD, talks about the increased risk of tardive dyskinesia on a synaptic level.

Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.

Related Videos
New Africa /Adobestock
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Related Content
valbenazine
May 16th 2025

New Ingrezza Data Demonstrates Functional and Quality of Life Improvements in Patients With Tardive Dyskinesia

Leah Kuntz
tardive versus spontaneous dyskinesia
April 17th 2019

Not All That Writhes Is Tardive Dyskinesia

Chris Aiken, MD
phase 1
March 5th 2025

Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions

Leah Kuntz
tardive dyskinesia
February 27th 2025

Significant Improvements in Functionality and Quality of Life: New Data on Ingrezza for Tardive Dyskinesia

Leah Kuntz
innovation
December 10th 2024

Psychopharmacology Innovations

John J. Miller, MD
tardive dyskinesia
September 24th 2024

Deutetrabenazine Shows Long Term Efficacy and Safety in Patients with Tardive Dyskinesia

Leah Kuntz
© 2025 MJH Life Sciences

All rights reserved.